logo
Products
Services
Resources
Selection Guides
About
APC/Cy7 Anti-human CD8 Antibody
HIT8a
The HIT8a monoclonal antibody binds to human CD8a, a 32 - 34 kD member of the Ig superfamily often located on the surface of dendritic cells, t cells and thymocytes. CD8 is a component of important cellular pathways, namely, the transmembrane receptor protein tyrosine kinase signaling pathway and cell surface receptor signaling pathway. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands like Lck and MHCI. CD8 is a very popular antibody target, with over 125000 publications in the last decade. CD8a is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology. This antibody was purified through affinity chromatography and conjugated to APC/Cy7 (ex/em = 754/779 nm).
Flow cytometry analysis of whole blood stained with APC-Cy7 anti-human CD8 *HIT8a* conjugate. The fluorescence signal was monitored using an Aurora spectral flow cytometer in the APC-Cy7 specific R7-A channel.
Flow cytometry analysis of whole blood stained with APC-Cy7 anti-human CD8 *HIT8a* conjugate. The fluorescence signal was monitored using an Aurora spectral flow cytometer in the APC-Cy7 specific R7-A channel.
CatalogSize
Price
Quantity
100801D025 tests
Price
100801D1100 tests
Price
100801D2500 tests
Price
 
Antibody properties

Other namesT8, Leu2
CloneHIT8a
HostMouse
IsotypeIgG1
ReactivityHuman
Spectral properties

Extinction coefficient (cm -1 M -1)
700000
Excitation (nm)651
Emission (nm)779
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on April 4, 2026